NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) gapped up before the market opened on Thursday . The stock had previously closed at $20.05, but opened at $21.14. NewAmsterdam Pharma shares last traded at $20.34, with a volume of 27,516 shares trading hands.
Analyst Ratings Changes
Several equities analysts have recently commented on the company. Piper Sandler assumed coverage on NewAmsterdam Pharma in a report on Tuesday, January 16th. They set an "overweight" rating and a $37.00 target price for the company. Royal Bank of Canada increased their price objective on NewAmsterdam Pharma from $25.00 to $31.00 and gave the stock an "outperform" rating in a report on Thursday, February 29th. Guggenheim started coverage on NewAmsterdam Pharma in a report on Thursday, January 18th. They issued a "buy" rating and a $30.00 price objective for the company. Finally, Scotiabank started coverage on NewAmsterdam Pharma in a report on Thursday, March 14th. They issued a "sector outperform" rating and a $35.00 price objective for the company. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, NewAmsterdam Pharma has a consensus rating of "Buy" and a consensus price target of $33.25.
Check Out Our Latest Report on NewAmsterdam Pharma
NewAmsterdam Pharma Stock Performance
The business has a 50 day simple moving average of $21.50 and a 200-day simple moving average of $15.23.
Insider Buying and Selling at NewAmsterdam Pharma
In related news, Director Louis G. Lange acquired 5,000 shares of the business's stock in a transaction dated Tuesday, February 13th. The stock was bought at an average price of $19.00 per share, for a total transaction of $95,000.00. Following the transaction, the director now owns 24,878 shares of the company's stock, valued at $472,682. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. In related news, Director Louis G. Lange acquired 5,000 shares of the business's stock in a transaction dated Tuesday, February 13th. The stock was bought at an average price of $19.00 per share, for a total transaction of $95,000.00. Following the transaction, the director now owns 24,878 shares of the company's stock, valued at $472,682. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director James N. Topper acquired 8,429 shares of the business's stock in a transaction dated Tuesday, March 26th. The shares were bought at an average price of $21.50 per share, with a total value of $181,223.50. Following the transaction, the director now directly owns 3,008,429 shares in the company, valued at approximately $64,681,223.50. The disclosure for this purchase can be found here. 2.50% of the stock is currently owned by corporate insiders.
Institutional Investors Weigh In On NewAmsterdam Pharma
A number of institutional investors and hedge funds have recently modified their holdings of NAMS. Alyeska Investment Group L.P. purchased a new position in shares of NewAmsterdam Pharma during the fourth quarter valued at $1,892,000. Schonfeld Strategic Advisors LLC acquired a new position in shares of NewAmsterdam Pharma in the 1st quarter valued at about $399,000. Geode Capital Management LLC purchased a new stake in shares of NewAmsterdam Pharma in the first quarter worth approximately $249,000. JPMorgan Chase & Co. boosted its holdings in shares of NewAmsterdam Pharma by 1,929.7% during the first quarter. JPMorgan Chase & Co. now owns 22,367 shares of the company's stock worth $301,000 after purchasing an additional 21,265 shares during the period. Finally, Marshall Wace LLP acquired a new position in shares of NewAmsterdam Pharma in the second quarter worth $302,000. Institutional investors and hedge funds own 89.89% of the company's stock.
About NewAmsterdam Pharma
(
Get Free Report)
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.
Featured Stories
Before you consider NewAmsterdam Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NewAmsterdam Pharma wasn't on the list.
While NewAmsterdam Pharma currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
